Latest Genetic disorders Stories
The commonly-used epilepsy drug, valproic acid (VPA), can have a highly beneficial effect on some babies born with spinal muscular atrophy (SMA), the number one genetic killer during early infancy.
Leading muscular dystrophy researcher Dean Burkin, of the University of Nevada School of Medicine summarizes the impact of a new protein therapeutic, MG53, for the treatment of Duchenne muscular dystrophy in an article published this week in Science Translational Medicine.
Strategic focus and robust portfolio of services continue to create record distribution trend for specialty biotech distributor BDI Pharma. Columbia, SC (PRWEB)
More than 15,000 Americans have Huntington’s disease, a fatal condition marked by uncontrolled movements and cognitive and psychiatric problems. Currently, there are no available treatments to alter the effects of Huntington’s disease, but a new study brings researchers one step closer to finding one.
With a single drug treatment, researchers at the Ludwig Institute for Cancer Research at the University of California, San Diego School of Medicine can silence the mutated gene responsible for Huntington's disease, slowing and partially reversing progression of the fatal neurodegenerative disorder in animal models.
A new gene-silencing strategy can reverse core symptoms associated with Huntington's disease.
The Munchkin is a fairly new breed of cat with a lot of controversy surrounding it. The breed is created by a mutation that causes achondroplasia, or hypochondroplasia, which results in the cats having abnormally short legs. The breed originated when a pregnant, short-legged black cat was discovered in Louisiana in 1983. One of her kittens, a tomcat, became the father of the breeding program for Munchkins. Several cat registries refuse to recognize the breed due to the controversy that...
More Images (2 images) »